Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Interest Expenses (2016 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Interest Expenses for 9 consecutive years, with $1.3 million as the latest value for Q3 2023.

  • For Q3 2023, Interest Expenses rose 58.73% year-over-year to $1.3 million; the TTM value through Jun 2024 reached $1.3 million, down 59.83%, while the annual FY2023 figure was $2.8 million, 6.53% down from the prior year.
  • Interest Expenses hit $1.3 million in Q3 2023 for Cartesian Therapeutics, up from $752000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $1.3 million in Q3 2023 and bottomed at $205000.0 in Q2 2020.
  • Average Interest Expenses over 5 years is $620157.9, with a median of $711000.0 recorded in 2021.
  • Year-over-year, Interest Expenses skyrocketed 5683.33% in 2019 and then tumbled 48.75% in 2020.
  • Cartesian Therapeutics' Interest Expenses stood at $335000.0 in 2019, then surged by 112.84% to $713000.0 in 2020, then fell by 0.28% to $711000.0 in 2021, then grew by 13.5% to $807000.0 in 2022, then soared by 57.74% to $1.3 million in 2023.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $1.3 million, $752000.0, and $808000.0 for Q3 2023, Q2 2023, and Q1 2023 respectively.